C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 3; pp. 1902 - 1906
• Main Authors: Zhao, Dongming, Fukuyama, Satoshi, Sakai-Tagawa, Yuko, Takashita, Emi, Shoemaker, Jason E., Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.03.2016
• Subjects: Animals; Antiviral Agents; Antiviral Agents - pharmacology; Benzoates; Benzoates - pharmacology; Cell Line; CREB-Binding Protein; CREB-Binding Protein - antagonists & inhibitors; CREB-Binding Protein - metabolism; Dogs; E1A-Associated p300 Protein; E1A-Associated p300 Protein - antagonists & inhibitors; E1A-Associated p300 Protein - metabolism; HEK293 Cells; Histone Acetyltransferases; Histone Acetyltransferases - antagonists & inhibitors; Humans; Influenza A virus; Influenza A virus - drug effects; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Orthomyxoviridae Infections - drug therapy; Pyrazoles; Pyrazoles - pharmacology

New strategies to develop novel broad-spectrum antiviral drugs against influenza virus infections are needed due to the emergence of antigenic variants and drug-resistant viruses. Here, we evaluated C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase (HAT), as an...